|
MRPL49 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
3.04169999998383E-06 |
| Normal-vs-Stage3 |
4.44089209850063E-15 |
| Normal-vs-Stage4 |
1.62758695410048E-12 |
| Stage1-vs-Stage2 |
7.911700E-02 |
| Stage1-vs-Stage3 |
1.720610E-01 |
| Stage1-vs-Stage4 |
2.462000E-02 |
| Stage2-vs-Stage3 |
1.718060E-02 |
| Stage2-vs-Stage4 |
2.443400E-03 |
| Stage3-vs-Stage4 |
2.789200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
3.56750000000128E-05 |
| Normal-vs-Asian |
6.85570489267207E-11 |
| Caucasian-vs-AfricanAmerican |
2.217200E-01 |
| Caucasian-vs-Asian |
6.915200E-01 |
| AfricanAmerican-vs-Asian |
3.896600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-15 |
| Normal-vs-Female |
1.62481139653892E-12 |
| Male-vs-Female |
1.092800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.626032641866E-12 |
| Normal-vs-Age(41-60Yrs) |
8.30446822419617E-14 |
| Normal-vs-Age(61-80Yrs) |
1.66999747364116E-12 |
| Normal-vs-Age(81-100Yrs) |
4.49240000000017E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.302000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.963000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.365800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.321200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.190800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.752200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.035570E-03 |
| Classical-VS-Follicular |
2.424600E-01 |
| Classical-VS-Other |
3.937200E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
6.811900E-04 |
| Tall-VS-Other |
7.649800E-01 |
| Tall-VS-Normal |
1.77635683940025E-15 |
| Follicular-VS-Other |
3.135200E-01 |
| Follicular-VS-Normal |
3.94350000432198E-08 |
| Other-VS-Normal |
2.206400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.26785257240181E-12 |
| Normal-vs-N1 |
2.66453525910038E-15 |
| N0-vs-N1 |
5.025000E-04 |
|
|
